LHRH-A治疗前列腺癌去势后复发转移疗效的探讨(附5例报告)(4)
参考文献
(1) 上海第一医学院《实用内科学》编写组编：实用内科学 北京 人民卫生出版社 1973 p.1114-1134
(2) Labrie F, Belanger A, Dupont A et al: Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 1993 Vol 16 No.6 pp475-492
(3) Schroder F H: Endocrine treatment of prostate cancer, in the Walsh Retik Vaughan Wein: CAMPBELL'S UROLOGY Seventh Edition Philadelphia, W. B. Saungers Co., 1998 pp2627-2644
(4) Soloway M S: Newer methods of hormonal therapy for prostate cancer. Supplement to UROLOGY 1984 vol XXIV No.5:30-38
(5) Bono A V: Leuprorelin-Continuing Advances in the Treatment of Prostate Cancer in the International Update on Leuprorelin. Biomedis 1997 No.2 pp4-13
(6) Okada H, Doken Y and Ogawa Y et al: Sustaied suppresion of the pituitary gonadal axis by leuororelin three-month depot microspheeres in rats and dogs. Phamaceutical Research 1994 vol. 11(8):1199
(7) Labrie F: At the Cutting Edge Intracrinology. Molecular and Cellular Endocrinology 1991 78: C113-C118
(8) Parmar H. Edwards L. And Phillips R H.et al: Orchiectomy versus Long-acting D-Trp-6-LHRH in Advanced Prostatic Cancer. British J. Urol. 1987 59 248-254
(9) Neumann F.and Kalmus J:Physiological principles of androgen regulation in the Hormonal Treatment of Sexual Deviations. Berlin Diesbach 1991 pp8-11
(10) Niijima T.and Aso Y.et al: Clinical phase I and phase II study on a sustrained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH Agonist, in patients with prostatic cncer. Acta Urologica Japonica 1990 36, 1343-1360
(11) Paulson D. F.: Role of Endocrine Therapy in the Management of Prostatic Cancer in the Skinner and Lieskovsky: Diagnosis and Management of Genitourinary Cancer. W. B. Saunders Co., Philadelphia 1988 pp464-472
(12) Grayhack JT, Bunce PL, Kearns JW, Scott WW: Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp. 1955; 96:154-163
(13) Schally AV, Redding TW: Somatostatin anlogos as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc. Natl. Acad. Sci. USA 1987 84:7275-7279
(14) Kadar T, Redding TW, Ben-David and Schally AV: Receptors for prolactin, somatostatin, and luteinizing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatistatin. Proc. Natl. Acad. Sci. USA 1988 85: 890-894, http://www.100md.com(李炎唐)
(1) 上海第一医学院《实用内科学》编写组编：实用内科学 北京 人民卫生出版社 1973 p.1114-1134
(2) Labrie F, Belanger A, Dupont A et al: Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 1993 Vol 16 No.6 pp475-492
(3) Schroder F H: Endocrine treatment of prostate cancer, in the Walsh Retik Vaughan Wein: CAMPBELL'S UROLOGY Seventh Edition Philadelphia, W. B. Saungers Co., 1998 pp2627-2644
(4) Soloway M S: Newer methods of hormonal therapy for prostate cancer. Supplement to UROLOGY 1984 vol XXIV No.5:30-38
(5) Bono A V: Leuprorelin-Continuing Advances in the Treatment of Prostate Cancer in the International Update on Leuprorelin. Biomedis 1997 No.2 pp4-13
(6) Okada H, Doken Y and Ogawa Y et al: Sustaied suppresion of the pituitary gonadal axis by leuororelin three-month depot microspheeres in rats and dogs. Phamaceutical Research 1994 vol. 11(8):1199
(7) Labrie F: At the Cutting Edge Intracrinology. Molecular and Cellular Endocrinology 1991 78: C113-C118
(8) Parmar H. Edwards L. And Phillips R H.et al: Orchiectomy versus Long-acting D-Trp-6-LHRH in Advanced Prostatic Cancer. British J. Urol. 1987 59 248-254
(9) Neumann F.and Kalmus J:Physiological principles of androgen regulation in the Hormonal Treatment of Sexual Deviations. Berlin Diesbach 1991 pp8-11
(10) Niijima T.and Aso Y.et al: Clinical phase I and phase II study on a sustrained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH Agonist, in patients with prostatic cncer. Acta Urologica Japonica 1990 36, 1343-1360
(11) Paulson D. F.: Role of Endocrine Therapy in the Management of Prostatic Cancer in the Skinner and Lieskovsky: Diagnosis and Management of Genitourinary Cancer. W. B. Saunders Co., Philadelphia 1988 pp464-472
(12) Grayhack JT, Bunce PL, Kearns JW, Scott WW: Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp. 1955; 96:154-163
(13) Schally AV, Redding TW: Somatostatin anlogos as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc. Natl. Acad. Sci. USA 1987 84:7275-7279
(14) Kadar T, Redding TW, Ben-David and Schally AV: Receptors for prolactin, somatostatin, and luteinizing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatistatin. Proc. Natl. Acad. Sci. USA 1988 85: 890-894, http://www.100md.com(李炎唐)